## Maxime Meylan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5351140/publications.pdf

Version: 2024-02-01

933264 1125617 1,171 16 10 13 citations g-index h-index papers 18 18 18 825 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 2022, 55, 527-541.e5.	6.6	215
2	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
3	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
4	Les structures lymphoÃ <sup>-</sup> des tertiaires génÃ <sup>-</sup> rent et propagent des plasmocytes produisant desÂanticorps antitumoraux dans le cancer du rein. Medecine/Sciences, 2022, 38, 536-538.	0.0	0
5	An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 680435.	2.2	28
6	Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS ONE, 2021, 16, e0252026.	1.1	12
7	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunology Research, 2021, 9, 891-908.	1.6	43
8	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, 2021, 12, 701273.	2.2	5
9	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical Cancer Research, 2021, 27, 6749-6760.	3.2	39
10	B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218, .	4.2	91
11	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
12	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
13	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Seminars in Immunology, 2020, 48, 101406.	2.7	44
14	TAMI-51. IDENTIFYING NEW TUMOR MICROENVIRONMENT (TME) CONTEXTS OF VULNERABILITY IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii224-ii224.	0.6	1
15	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339
16	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clinical Cancer Research, 2020, 26, 4381-4389.	3.2	44